Rarebase, a privately held public benefit corporation pioneering a new approach to biotech, is the first public benefit corporation, focused on rare disease therapeutics, to enroll in the "Our Lives Matter" DEI Initiative, a community-developed diversity, equity and inclusion (DEI) research and educational initiative.

Successfully enrolling the minimum of five required participants, Rarebase's participation in the "Our Lives Matter" DEI unLearning program is a testament to their dedication to partnering with patient organizations on translational therapeutic discovery and development.

In addition to the active enrollment into the "Our Lives Matter" DEI unLearning program, the team at Rarebase has also enrolled into the "Our Lives Matter" Certification program. Upon completion of the certification program, will be eligible to receive the "Our Lives Matter" DEI Certified digital badge.